𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I–II trial of heavy charged particle irradiation of malignant glioma of the brain: A Northern California oncology group study

✍ Scribed by J.R. Castro; W.M. Saunders; M.M. Austin-Seymour; K.H. Woodruff; G. Gauger; G.T.Y. Chen; J.M. Collier; T.L. Phillips; S.R. Zink

Publisher
Elsevier Science
Year
1985
Tongue
English
Weight
957 KB
Volume
11
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final report of a phase I/II trial of hy
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83-02
✍ Maria Werner-Wasik; Charles B. Scott; Diana F. Nelson; Laurie E. Gaspar; Kevin J 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 825 KB

## BACKGROUND. Efforts to improve local control and survival by increasing the dose of once-daily radiation therapy beyond 70 Gray (Gy) for patients with malignant gliomas have as yet been unsuccessful. Hyperfractionated radiation therapy (HF) should allow for delivery of a higher total dose witho

Phase II trial of cis-dichlorodiamminepl
Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B
✍ F. Cavalli; Dr. W. F. Jungi; N. I. Nissen; T. F. Pajak; M. Coleman; J. F. Hollan 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 3 views

In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of cisdichlorodiammineplatinum(l1) (cis-platinum) once every three weeks. All patients had received extensive prior therapy. Partial remission was obtai

Phase II study of α2 interferon in the t
Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487) : A trial of the Eastern Cooperative Oncology Group
✍ Arthur I. Radin; Haesook T. Kim; Barbara W. Grant; John M. Bennett; John M. Kirk 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract ## BACKGROUND In vitro and clinical data suggest a therapeutic role for α2 interferon (IFN) in the treatment of the chronic myeloproliferative disorders. Accordingly, a multiinstitutional, Phase II trial of IFN in patients with agnogenic myeloid metaplasia (AMM), essential thrombocythe